Am­per­sand snags $50M as Flag­ship fo­cus­es ther­a­peu­tics on de­sired tar­gets on­ly 

The be­he­moth biotech cre­ator Flag­ship Pi­o­neer­ing is out with an­oth­er start­up aim­ing to achieve the crown jew­el of drug de­vel­op­ment: treat­ments that hit on­ly the de­sired tar­get and cause no un­want­ed ef­fects else­where.

Am­per­sand Bio­med­i­cines is the Boston in­cu­ba­tor’s lat­est biotech to open its blinds, with Flag­ship dish­ing out a $50 mil­lion check to bankroll ini­tial work.

Lead­ing the charge at Am­per­sand is Flag­ship gen­er­al part­ner Avak Kahve­jian, who’s al­so found­ing CEO of Pro­Found Ther­a­peu­tics and has been in­volved in the ear­ly days of mul­ti­ple oth­er com­pa­nies formed by the en­gine that sparked Mod­er­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER